6/25/22
Van Egeren et al, Harvard, PLOS, explains how mutations render the mandated products useless but still has enough RBD integrity to cause infection.  The worldwide failure of the program occurred with a narrow band of epitopes had no hope for durable protection. Anticipated.
– Dr. Peter McCullough
Join  @PeterMcCullough